New Guideline on Managing Colorectal Cancer.

Abstract:

:A multidisciplinary panel of experts has issued guidelines that consolidate current evidence on testing for molecular biomarkers in colorectal cancer. The guidelines aim to standardize molecular testing for patients with colorectal cancer and help clinicians identify patients most likely to benefit from targeted treatments.

journal_name

Cancer Discov

journal_title

Cancer discovery

authors

doi

10.1158/2159-8290.CD-NB2017-030

subject

Has Abstract

pub_date

2017-04-01 00:00:00

pages

OF2

issue

4

eissn

2159-8274

issn

2159-8290

pii

2159-8290.CD-NB2017-030

journal_volume

7

pub_type

杂志文章
  • Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.

    abstract:: In this issue Grommes and colleagues elegantly show that the irreversible inhibitor of Bruton tyrosine kinase, ibrutinib, promotes a high proportion of durable responses in primary central nervous system lymphoma, a type of diffuse large B-cell lymphoma (DLBCL), and also in secondary DLBCL relapsing to the centra...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-17-0714

    authors: Lakshmanan A,Byrd JC

    更新日期:2017-09-01 00:00:00

  • Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.

    abstract::Loss-of-function mutations in JAK1/2 can lead to acquired resistance to anti-programmed death protein 1 (PD-1) therapy. We reasoned that they may also be involved in primary resistance to anti-PD-1 therapy. JAK1/2-inactivating mutations were noted in tumor biopsies of 1 of 23 patients with melanoma and in 1 of 16 pati...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-16-1223

    authors: Shin DS,Zaretsky JM,Escuin-Ordinas H,Garcia-Diaz A,Hu-Lieskovan S,Kalbasi A,Grasso CS,Hugo W,Sandoval S,Torrejon DY,Palaskas N,Rodriguez GA,Parisi G,Azhdam A,Chmielowski B,Cherry G,Seja E,Berent-Maoz B,Shintaku IP,L

    更新日期:2017-02-01 00:00:00

  • Database Drives Biomarker Research.

    abstract::The Genomics of Drug Sensitivity in Cancer project recently added 4 years of additional data to a large-scale database designed to identify predictive biomarkers for cancer therapies. Freely available online, these data are driving research on the relationship between genomic features and drug responses to better tail...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2019-114

    authors:

    更新日期:2019-11-01 00:00:00

  • Drugs, diagnostic tests approved quickly.

    abstract::Accelerated review and greater understanding of tumor biology speed targeted treatments to patients. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-ND11-09

    authors: Rose S

    更新日期:2011-10-01 00:00:00

  • High-risk women should have BRCA testing.

    abstract::The U.S. Preventive Services Task Force released new guidelines recommending BRCA mutation testing be limited to high-risk women who have received genetic counseling. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2014-003

    authors:

    更新日期:2014-02-01 00:00:00

  • LXR agonism inhibits metastatic melanoma through activation of ApoE.

    abstract::Nuclear hormone receptor targeting suppresses melanoma progression in diverse preclinical models. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2014-056

    authors:

    更新日期:2014-05-01 00:00:00

  • Two Worlds Collide: Unraveling the Role of the Immune System in BRAF-MEK Inhibitor Responses.

    abstract::Although BRAF-MEK inhibition can enhance the immune recognition of melanoma cells, the mechanisms that underlie this remain poorly defined. In this issue of Cancer Discovery, Erkes and colleagues present new data showing that BRAF-MEK inhibition activates pyroptosis in melanoma cells through gasdermin E cleavage, lead...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-19-1441

    authors: Smalley KSM

    更新日期:2020-02-01 00:00:00

  • ADC Could Benefit Some with Breast Cancer.

    abstract::Results from a phase I/II trial suggest that an antibody-drug conjugate, sacituzumab govitecan, is active against refractory, metastatic triple-negative breast cancer. A phase III trial is under way to compare its safety and efficacy with that of standard chemotherapy. ...

    journal_title:Cancer discovery

    pub_type: 评论,新闻

    doi:10.1158/2159-8290.CD-NB2019-034

    authors:

    更新日期:2019-05-01 00:00:00

  • Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.

    abstract::HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers. We assessed the safety/tolerability and activity of the novel HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in 60 patients with pretreated, HER2-expressing (IHC ≥ 1+), non-breast/non-gastric or HER2-mutant so...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-19-1014

    authors: Tsurutani J,Iwata H,Krop I,Jänne PA,Doi T,Takahashi S,Park H,Redfern C,Tamura K,Wise-Draper TM,Saito K,Sugihara M,Singh J,Jikoh T,Gallant G,Li BT

    更新日期:2020-05-01 00:00:00

  • Pemigatinib Is Active in Some FGFR2-Altered Cholangiocarcinomas.

    abstract::Pemigatinib was effective in patients with cholangiocarcinomas with FGFR2 fusions or rearrangements. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2020-050

    authors:

    更新日期:2020-05-01 00:00:00

  • First Comprehensive Companion Diagnostic OK'd.

    abstract::The FDA has approved F1CDx, a comprehensive companion diagnostic test that can detect genetic alterations and two genomic signatures in any type of solid tumor. Patients with five common types of advanced cancer can be matched to one of 17 targeted therapies with this single test. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-182

    authors:

    更新日期:2018-03-01 00:00:00

  • Palmitoylation Alters STAT3 Activity and Tumor Response to High-Fat Diet.

    abstract::STAT3 palmitoylation increases dimerization, nuclear localization, and activation of target genes. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2019-139

    authors:

    更新日期:2019-09-06 00:00:00

  • ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.

    abstract:UNLABELLED:ARID1A, SWI/SNF chromatin remodeling complex subunit, is a recently identified tumor suppressor that is mutated in a broad spectrum of human cancers. Thus, it is of fundamental clinical importance to understand its molecular functions and determine whether ARID1A deficiency can be exploited therapeutically. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-14-0849

    authors: Shen J,Peng Y,Wei L,Zhang W,Yang L,Lan L,Kapoor P,Ju Z,Mo Q,Shih IeM,Uray IP,Wu X,Brown PH,Shen X,Mills GB,Peng G

    更新日期:2015-07-01 00:00:00

  • High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.

    abstract:UNLABELLED:Knowledge of "actionable" somatic genomic alterations present in each tumor (e.g., point mutations, small insertions/deletions, and copy-number alterations that direct therapeutic options) should facilitate individualized approaches to cancer treatment. However, clinical implementation of systematic genomic ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-11-0184

    authors: Wagle N,Berger MF,Davis MJ,Blumenstiel B,Defelice M,Pochanard P,Ducar M,Van Hummelen P,Macconaill LE,Hahn WC,Meyerson M,Gabriel SB,Garraway LA

    更新日期:2012-01-01 00:00:00

  • Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.

    abstract::Despite recent advances in the use of immunotherapy, only a minority of patients with small cell lung cancer (SCLC) respond to immune checkpoint blockade (ICB). Here, we show that targeting the DNA damage response (DDR) proteins PARP and checkpoint kinase 1 (CHK1) significantly increased protein and surface expression...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-18-1020

    authors: Sen T,Rodriguez BL,Chen L,Corte CMD,Morikawa N,Fujimoto J,Cristea S,Nguyen T,Diao L,Li L,Fan Y,Yang Y,Wang J,Glisson BS,Wistuba II,Sage J,Heymach JV,Gibbons DL,Byers LA

    更新日期:2019-05-01 00:00:00

  • XPO1 Inhibitor Approved for Multiple Myeloma.

    abstract::The FDA granted accelerated approval to selinexor plus low-dose dexamethasone for triple-class refractory multiple myeloma, despite an advisory panel's concerns about the drug's toxicity and the lack of randomized clinical data. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2019-085

    authors:

    更新日期:2019-09-01 00:00:00

  • Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine.

    abstract:UNLABELLED:The relationships between telomerase and telomeres represent attractive targets for new anticancer agents. Here, we report that the nucleoside analogue 6-thio-2'-deoxyguanosine (6-thio-dG) is recognized by telomerase and is incorporated into de novo-synthesized telomeres. This results in modified telomeres, ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-14-0609

    authors: Mender I,Gryaznov S,Dikmen ZG,Wright WE,Shay JW

    更新日期:2015-01-01 00:00:00

  • Granule Neuron Precursor-Derived Astrocytes Promote Medulloblastoma.

    abstract::Granule neuron precursors transdifferentiate into astrocytes in the tumor microenvironment. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-RW2020-016

    authors:

    更新日期:2020-03-01 00:00:00

  • Tumor Profiling: Adding Proteomics to Genomics.

    abstract::Researchers have used mass spectrometry to conduct proteomic analyses of 77 genomically characterized breast tumors. Through this approach, they've uncovered functional consequences of somatic mutations. For instance, EGFR overexpression in basal-like breast cancer is potentially driven by the loss of two genes, SKP1 ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2016-078

    authors:

    更新日期:2016-08-01 00:00:00

  • Cancer "Clock" Opens New Therapeutic Avenues.

    abstract::Long ignored, the importance of circadian rhythms-the focus of this year's Nobel Prize in Physiology or Medicine-is beginning to gain attention from researchers interested in cancer prevention, drug discovery, and therapeutic optimization. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-149

    authors:

    更新日期:2017-12-01 00:00:00

  • Discovery may hike stem cell transplants.

    abstract::Researchers identified a small molecule that stimulates the production of stem cells in umbilical cord blood, potentially expanding treatment options for adults with hematologic cancers. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2014-153

    authors:

    更新日期:2014-12-01 00:00:00

  • Enzalutamide Bests Older NSAAs in mHSPC.

    abstract::According to results from ENZAMET, a global phase III trial, adding enzalutamide to standard treatment for men with metastatic hormone-sensitive prostate cancer is superior in prolonging survival compared with older nonsteroidal antiandrogen drugs. ...

    journal_title:Cancer discovery

    pub_type: 评论,新闻

    doi:10.1158/2159-8290.CD-NB2019-066

    authors:

    更新日期:2019-08-01 00:00:00

  • From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer.

    abstract::DNA repair deficiencies are common among cancer cells and represent a potential vulnerability that might be exploited by targeting compensatory repair pathways. However, the identification of synthetically lethal combinations of DNA repair defects, although of significant clinical relevance, has been somewhat anecdota...

    journal_title:Cancer discovery

    pub_type:

    doi:10.1158/2159-8290.CD-14-0316

    authors: Hemann MT

    更新日期:2014-05-01 00:00:00

  • Not expecting the unexpected: diacylglycerol kinase alpha as a cancer target.

    abstract::In this issue of Cancer Discovery, Dominguez and colleagues identify diacylglycerol kinase alpha (DGKα), an enzyme that converts the membrane lipid diacylglycerol to phosphatidic acid, as a central node upstream of mTOR and other oncogenic pathways. Importantly, targeting DGKα causes apoptosis in cancer cells and tumo...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-13-0244

    authors: Bhat KP,Aldape K

    更新日期:2013-07-01 00:00:00

  • Durable Responses with Brentuximab Vedotin in cHL.

    abstract::According to survival results from a phase II trial of brentuximab vedotin, 34 patients with relapsed or refractory classic Hodgkin lymphoma had a complete response with this CD30-targeting antibody-drug conjugate; 13 remain in remission 5 years later. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2016-100

    authors:

    更新日期:2016-09-01 00:00:00

  • Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.

    abstract:UNLABELLED:Identifying genetic alterations that prime a cancer cell to respond to a particular therapeutic agent can facilitate the development of precision cancer medicines. Cancer cell-line (CCL) profiling of small-molecule sensitivity has emerged as an unbiased method to assess the relationships between genetic or c...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-15-0235

    authors: Seashore-Ludlow B,Rees MG,Cheah JH,Cokol M,Price EV,Coletti ME,Jones V,Bodycombe NE,Soule CK,Gould J,Alexander B,Li A,Montgomery P,Wawer MJ,Kuru N,Kotz JD,Hon CS,Munoz B,Liefeld T,Dančík V,Bittker JA,Palmer M,

    更新日期:2015-11-01 00:00:00

  • Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers.

    abstract::Translational data on chimeric antigen receptor (CAR) T-cell trials indicate that the presence of naïve T cells in the premanufacture product is important to clinical response and persistence. In anticipation of developing CAR trials for other tumors, we investigated the T-cell distribution from children with solid tu...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-18-1314

    authors: Das RK,Vernau L,Grupp SA,Barrett DM

    更新日期:2019-04-01 00:00:00

  • Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma.

    abstract:UNLABELLED:Adenoid cystic carcinoma (ACC), the second most common malignancy of salivary glands, is a rare tumor with a bleak prognosis for which therapeutic targets are unavailable. We used RNA sequencing (RNA-seq) to analyze low-quality RNA from archival, formaldehyde-fixed, paraffin-embedded samples. In addition to ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-15-0859

    authors: Brayer KJ,Frerich CA,Kang H,Ness SA

    更新日期:2016-02-01 00:00:00

  • Blocking IDO1 Helps Shrink Bladder, Cervical Tumors.

    abstract::Findings from a phase I/IIa study indicate that combining the investigational indoleamine 2,3-dioxygenase 1 inhibitor BMS-986205 with nivolumab is safe and boosts response rates among patients with bladder and cervical cancers. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-167

    authors:

    更新日期:2018-01-01 00:00:00

  • Tweaking Transcription to Stop AML Cell Growth.

    abstract::A new compound with anti-leukemia activity perturbs gene transcription by modulating super-enhancer activity. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2015-149

    authors:

    更新日期:2015-12-01 00:00:00